CD274 and hepatocellular carcinoma: Strikingly, blocking the interaction between programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has presented a substantial survival benefit in an open-label, non-comparative, phase 1/2 dose escalation and expansion trial in advanced HCC patients (5).